Delving into the Latest Updates on Hainan Bikai Pharmaceutical Co. Ltd. with Synapse

Overview

Tags

Neoplasms

Infectious Diseases

Other Diseases

Herbal medicine

Disease domain score

A glimpse into the focused therapeutic areas

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

No Data

Disease Domain	Count

Infectious Diseases	1
Neoplasms	1

Top 5 Drug Type	Count

Herbal medicine	1

[Translation] A randomized, double-blind, placebo-controlled, multicenter phase II clinical trial to evaluate the efficacy and safety of Baofukang suppositories in the treatment of cervical high-risk human papillomavirus 16/18 (HR-HPV16/18) infection combined with low-grade squamous intraepithelial lesions (CINI/P16 negative CINII)

（1）探索保妇康栓治疗宫颈 HR-HPV16/18 感染合并 LSIL（CINI/P16 阴性的 CINII）的最佳给药方案。（2）初步评价保妇康栓治疗 HR-HPV16/18 感染合并 LSIL（CINI/P16 阴性的 CINII）的有效性和安全性。（3）初步评价保妇康栓治疗宫颈 HR-HPV16/18 感染的有效性和安全性。

[Translation]

(1) To explore the optimal dosing regimen of Baofukang suppository for the treatment of cervical HR-HPV16/18 infection combined with LSIL (CINI/P16 negative CINII). (2) To preliminarily evaluate the efficacy and safety of Baofukang suppository for the treatment of HR-HPV16/18 infection combined with LSIL (CINI/P16 negative CINII). (3) To preliminarily evaluate the efficacy and safety of Baofukang suppository for the treatment of cervical HR-HPV16/18 infection.

Start Date12 Mar 2021

Sponsor / Collaborator

Hainan Bikai Pharmaceutical Co. Ltd.

CTR20210286

/ RecruitingPhase 2

保妇康栓治疗宫颈高级别鳞状上皮内病变（P16阳性的CINII）有效性和安全性的随机、双盲、安慰剂平行对照、多中心II期临床试验

[Translation] A randomized, double-blind, placebo-controlled, multicenter phase II clinical trial on the efficacy and safety of Baofukang suppositories in the treatment of high-grade cervical squamous intraepithelial lesions (P16-positive CINII)

（1）探索保妇康栓治疗HSIL（P16阳性的CINII）的最佳给药方案。（2）初步评价保妇康栓治疗HSIL（P16阳性的CINII）的有效性和安全性。（3）初步评价保妇康栓治疗宫颈HR-HPV感染的有效性和安全性。

[Translation]

(1) To explore the optimal dosing regimen of Baofukang suppository for the treatment of HSIL (P16-positive CINII). (2) To preliminarily evaluate the efficacy and safety of Baofukang suppository for the treatment of HSIL (P16-positive CINII). (3) To preliminarily evaluate the efficacy and safety of Baofukang suppository for the treatment of cervical HR-HPV infection.

Start Date09 Mar 2021

Sponsor / Collaborator

Hainan Bikai Pharmaceutical Co. Ltd.

100 Clinical Results associated with Hainan Bikai Pharmaceutical Co. Ltd.

Login to view more data

0 Patents (Medical) associated with Hainan Bikai Pharmaceutical Co. Ltd.

Login to view more data

7

Literatures (Medical) associated with Hainan Bikai Pharmaceutical Co. Ltd.

18 Oct 2019·Natural Product ResearchQ3 · CHEMISTRY

Three new labdane-type diterpenoids from Callicarpa macrophylla Vahl.

Q3 · CHEMISTRY

Article

Author: Yang, Lan-Ping ; Zhang, Qing-Ling ; Meng, Yue-Li ; Zhang, Yan-Ru ; Zhai, Yang-Yang ; Niu, Chao ; Zhang, Wen-Kui ; Li, Qiang ; Wang, Zhen-Hui ; Xu, Huan-Jun ; Huang, Mei ; Chen, Xing-Ying

Three new labdane-type diterpenoids, callicapene M3-M5 (1-3) were isolated from the Callicarpa macrophylla Vahl. Their structures were identified by spectroscopic method. The isolated compounds were evaluated for inhibitory activity on NO production in LPS-activated RAW 264.7 macrophage cells by using MTT assays. Compounds 1-3 showed potent inhibitory activity, with IC₅₀ value of 48.15, 46.31 and 38.72 μM respectively.

Zhongnan Yaoxue

Tissue distribution and excretion of docetaxel submicron emulsion

Author: Shi, Chaohui ; Tan, Yinfeng ; Liu, Qiang ; Kuang, Shaoyi ; Fu, Naiguang ; Tang, Jing ; Zhang, Li

The tissue distribution and excretion of docetaxel submicron emulsion in rats were investigated.A high-performance liquid chromatog. (HPLC) with UV detection was developed to study the concentration of docetaxel in the biol. samples.Taking paclitaxel as an internal standard, 48 SD rats were randomly divided into 2 groups: test preparation and reference preparation, and each group was i.v. administered 75 mg·m^-2 DTX.The rats were executed at 5, 30, 60 and 300 min, and tissues were taken in the same location to determine the content.The docetaxel submicron emulsion was widely distributed in the tissues of the body.The docetaxel concentration of the test group in the heart and lung was lower than that of the reference group, but higher than the reference group in the spleen.In the kidney, the docetaxel concentration of the test group increased quickly before 30 min and was higher than the reference group, and after that the concentration decreased even lower than the reference injection.The docetaxel concentrations of the 2 groups in other tissues and organs had no significant difference.The excretion of the parent drug in the urine and excrement amounted to 2% and 6% of the dose, resp.Submicron emulsion had no significant effect on docetaxel distribution, and the preparation was delivered effectively.In safety and pharmacodynamic evaluation, more attention should be paid to the alteration of toxicity and therapeutic effect after changing dosage forms.

Zhongguo Xinyao Zazhi

Preparation of dirithromycin enteric-coated pellets by centrifugal granulation technology

Author: Zhang, Chun-ye ; Cui, Wen-qi ; Wang, Dong-kai ; Yao, Jian-mei ; Gao, Fei ; Yin, Dong-er

To prepare the dirithromycin enteric-coated pellets.The dirithromycin enteric-coated pellets were prepared by centrifugal granulation and fluid-bed coating method.In the first 2 h, the dirithromycin enteric-coated pellets released less than 10% in pH 1.2 hydrochloric acid solution and then released more than 80% in pH 6.8 phosphoric buffer within 45 min.The preparation of dirithromycin enteric-coated pellets is feasible, and the quality of the pellets is reliable.

100 Deals associated with Hainan Bikai Pharmaceutical Co. Ltd.

Login to view more data

100 Translational Medicine associated with Hainan Bikai Pharmaceutical Co. Ltd.

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 31 Jan 2025

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Approved

1

Login to view more data